Watch for full AZUR-1 interim analysis data presentation at ESMO Congress October 2026 and regulatory decisions in Project Orbis participating countries. Monitor Jemperli prescription trends and potential label expansion into other MSI-H/dMMR solid tumors.
Price Chart
Executive Summary
GSK announced FDA approval of Jemperli (dostarlimab) as the first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer under accelerated approval. The approval is based on AZUR-1 trial data showing 68% of evaluable patients achieved sustained clinical complete response at 12 months, with no disease recurrences reported after median follow-up of more than two years. This expands Jemperli's addressable market into a new indication with potential to replace chemotherapy, radiation, and surgery for eligible patients.
Key Facts
- FDA approved Jemperli (dostarlimab) as first and only immunotherapy for stage II/III MSI-H/dMMR locally advanced rectal cancer under accelerated approval pathway
- Approval based on AZUR-1 phase II trial: 68% (98/144) of evaluable patients achieved clinical complete response at 12 months (cCR12) by investigator assessment
- No disease recurrences reported among responders after median follow-up of more than two years
- 76% (110/144) of evaluable patients had no evidence of cancer one year or more after treatment in exploratory analysis
- Jemperli received Fast Track, Breakthrough Therapy, Priority Review, and a National Priority Voucher, resulting in accelerated approval ahead of PDUFA date
- MSI-H/dMMR biomarker found in approximately 5-10% of rectal cancers
- Safety profile consistent with established profile across solid tumors; serious adverse reactions in 20% of patients, permanent discontinuation in 3%
Financial Impact
New indication expands Jemperli's addressable market into MSI-H/dMMR locally advanced rectal cancer, a biomarker-defined population representing ~5-10% of rectal cancers. No revenue figures or market size estimates provided in the filing.
Risk Factors
- Accelerated approval may require confirmatory trial data for full approval
- Competition from other PD-1/PD-L1 inhibitors seeking similar indications
- Limited addressable patient population (~5-10% of rectal cancers)
- Data on primary endpoint (cCR12 by independent central review) still maturing at 47% (54/116)
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-009036 |
| Document: 0001654954-26-009036-index-headers.html | 0001654954-26-009036 |
| Document: 0001654954-26-009036-index.html | 0001654954-26-009036 |
| Document: 0001654954-26-009036.txt | 0001654954-26-009036 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $51.10 | awaiting T+5 | — | $50.94 (−0.31%) |
Oct 26, 2026 1d ago | 6-K | $51.10 | awaiting T+5 | — | $50.94 (−0.31%) |
Oct 26, 2026 1d ago | 6-K | $51.10 | awaiting T+5 | — | $50.94 (−0.31%) |
Oct 26, 2026 1d ago | 6-K | $51.10 | awaiting T+5 | — | $50.94 (−0.31%) |
Oct 21, 2026 6d ago | 6-K | $50.02 | awaiting T+5 | — | $50.94 (+1.84%) |
Oct 19, 2026 8d ago | 6-K | $49.46 $51.10 | ▲ +3.32% | ▲ +3.46% | $50.94 (+2.99%) |
Oct 19, 2026 8d ago | 6-K | $49.46 $51.10 | ▲ +3.32% | ▲ +3.46% | $50.94 (+2.99%) |
Oct 15, 2026 12d ago | 6-K | $49.02 $51.21 | ▲ +4.47% | ▲ +5.48% | $50.94 (+3.92%) |
Oct 14, 2026 13d ago | 6-K | $47.87 $50.02 | ▲ +4.49% | ▲ +4.04% | $50.94 (+6.41%) |
Oct 13, 2026 14d ago | 6-K | $46.27 $50.63 | ▲ +9.42% | ▲ +10.57% | $50.94 (+10.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers